Eupraxia Pharmaceuticals Probability of Future Pink Sheet Price Finishing Over 2.79
| EPRXFDelisted Stock | USD 2.79 0.04 1.45% |
Eupraxia |
Eupraxia Pharmaceuticals Target Price Odds to finish over 2.79
The tendency of Eupraxia Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.79 | 90 days | 2.79 | about 70.2 |
Based on a normal probability distribution, the odds of Eupraxia Pharmaceuticals to move above the current price in 90 days from now is about 70.2 (This Eupraxia Pharmaceuticals probability density function shows the probability of Eupraxia Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 1.06 suggesting Eupraxia Pharmaceuticals market returns are reactive to returns on the market. As the market goes up or down, Eupraxia Pharmaceuticals is expected to follow. Additionally Eupraxia Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Eupraxia Pharmaceuticals Price Density |
| Price |
Predictive Modules for Eupraxia Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eupraxia Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eupraxia Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Eupraxia Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Eupraxia Pharmaceuticals is not an exception. The market had few large corrections towards the Eupraxia Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Eupraxia Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Eupraxia Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.84 | |
β | Beta against Dow Jones | 1.06 | |
σ | Overall volatility | 0.66 | |
Ir | Information ratio | -0.15 |
Eupraxia Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Eupraxia Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Eupraxia Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Eupraxia Pharmaceuticals is not yet fully synchronised with the market data | |
| Eupraxia Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals has accumulated about 35.46 M in cash with (14.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Zoth Lota S. of 367 shares of Lumos Pharma subject to Rule 16b-3 |
Eupraxia Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Eupraxia Pink Sheet often depends not only on the future outlook of the current and potential Eupraxia Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eupraxia Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 14.2 M |
Eupraxia Pharmaceuticals Technical Analysis
Eupraxia Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Eupraxia Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Eupraxia Pharmaceuticals. In general, you should focus on analyzing Eupraxia Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Eupraxia Pharmaceuticals Predictive Forecast Models
Eupraxia Pharmaceuticals' time-series forecasting models is one of many Eupraxia Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Eupraxia Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Eupraxia Pharmaceuticals
Checking the ongoing alerts about Eupraxia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Eupraxia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Eupraxia Pharmaceuticals is not yet fully synchronised with the market data | |
| Eupraxia Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals has accumulated about 35.46 M in cash with (14.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Zoth Lota S. of 367 shares of Lumos Pharma subject to Rule 16b-3 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world |